Transcode Therapeutics Inc Cash Flow Conversion Efficiency
Transcode Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Transcode Therapeutics Inc (RNAZ) has a cash flow conversion efficiency ratio of -0.039x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.40 Million) by net assets ($138.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Transcode Therapeutics Inc (2018–2025)
Cash flow conversion efficiency of Transcode Therapeutics Inc from 2018 to 2025. This chart illustrates how Transcode Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View RNAZ stock price and chart for real-time trading data and today's change.
Transcode Therapeutics Inc Cash Flow Conversion Ratio Explained
Transcode Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Transcode Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Transcode Therapeutics Inc ranked by their cash flow conversion efficiency. Also see market value of Transcode Therapeutics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vintage Energy Ltd
AU:VEN
|
0.191x |
|
Arctic Star Exploration Corp
V:ADD
|
-0.015x |
|
Northern 2 Vct Plc
LSE:NTV
|
-0.022x |
|
CDN Maverick Capital Corp.
F:338B
|
-0.123x |
|
Proven Growth and Income Vct PLC
LSE:PGOO
|
-0.008x |
|
Future Lifestyle Fashions Limited
NSE:FLFL
|
-0.089x |
|
Bakrieland Development Tbk
JK:ELTY
|
0.014x |
|
Cinis Fertilizer AB
ST:CINIS
|
-0.134x |
Annual Cash Flow Conversion Efficiency for Transcode Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Transcode Therapeutics Inc from 2018 to 2025. Review Transcode Therapeutics Inc (RNAZ) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $10.34 Million | $-19.52 Million | -1.888x | -128.58% |
| 2024-12-31 | $-2.02 Million | $-13.34 Million | 6.606x | +159.97% |
| 2023-12-31 | $1.64 Million | $-18.07 Million | -11.016x | -126.48% |
| 2022-12-31 | $3.24 Million | $-15.76 Million | -4.864x | -1784.33% |
| 2021-12-31 | $20.40 Million | $-5.27 Million | -0.258x | -278.46% |
| 2020-12-31 | $-3.41 Million | $-492.97K | 0.145x | -68.78% |
| 2019-12-31 | $-1.10 Million | $-508.51K | 0.463x | -22.05% |
| 2018-12-31 | $-503.97K | $-299.57K | 0.594x | -- |
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastati… Read more